Shanghai-Based Baiyi Medical, the Only Medical Device Finalist from Shanghai, Breaks into National Top 50 of 'Maker China' Innovation Competition with World’s First Automated Ocular Sign Measuring Device

Oct 21, 2025 17:45 CST Updated 17:45

Recently, the list of the top 50 national finalists for the 10th "Maker China" SME Innovation and Entrepreneurship Competition was announced, with three companies from Shanghai successfully selected. From Zhangjiang Science City in Shanghai,Shanghai Baiyi Medical Technology Co., Ltd., successfully selected with the project "World's First Automatic Ocular Feature Measuring Instrument", becoming the only biopharmaceutical company in Shanghai to enter the national finals in China, highlighting Zhangjiang's profound foundation in nurturing hardcore technology enterprises.

"Maker China" Witnesses the Continuous Rise of Zhangjiang's Innovative Strength

The "Maker China" SME Innovation and Entrepreneurship Competition is a competition jointly organized by the Ministry of Industry and Information Technology and the Ministry of Finance. It aims to focus on the industrial chain, deploy the innovation chain, and allocate the capital chain.It is one of the most influential innovation and entrepreneurship competitions in China.。

This competition covers 34 regional contests, 16 thematic contests, and 1 international contest across China, collecting tens of thousands of projects. The final selection of the top 50 enterprises in China will receive policy support, resource alignment, and investment attention, becoming the "seed players" leading industrial innovation.

As the core承载区 of Shanghai's biopharmaceutical industry,Zhangjiang Science City Assists Shanghai Baiyi Medical Technology Co., Ltd. in Breaking Through, Becoming the Sole Representative of China's Biomedical Field Among the Top 50 Nationwide, which not only fills the gap in Shanghai's presence among the top national tier in this field, but also further solidifies Zhangjiang's core position in China's biopharmaceutical innovation landscape.

World's First: Zhangjiang’s "Medical-Enterprise Integration" Solves Clinical Challenges

Shanghai Baiyi Medical Technology Co., Ltd. was established in 2020 as a high-tech enterprise rooted in Zhangjiang Science City, dedicated to the long-term research and development of diagnostic and treatment technologies and medical devices for thyroid-related diseases.

The award-winning "Automatic Eye Sign Measuring Instrument"，is a significant achievement of the 'medical-enterprise integration' innovative model in Zhangjiang——this device is the result of an in-depth collaboration between Shanghai Baiyi Medical Technology Co., Ltd. and Shanghai Ruijin Hospital, jointly promoting the major outcome of 'clinical innovation transformation', and also"The world's first medical device to achieve imaging-level quantitative diagnosis of thyroid eye disease。

This device integrates a precision optical system, multi-modal visual fusion technology, and AI algorithms, effectively addressing the clinical pain points of strong subjectivity and insufficient consistency in traditional manual measurements, achieving precise and quantitative diagnosis of thyroid eye disease. The product not only fills an international gap in this field but also provides global clinical diagnosis and treatment with a reliable objective evaluation tool. It has previously won top prizes in national innovation competitions, including securing first place nationwide in China's Medical Equipment Innovation Competition.

Zhangjiang Ecosystem Empowers the Creation of an Innovative "Source" for High-End Medical Equipment

On January 1, 2022, the first local industrial regulation in Shanghai, "Regulations of the Pudong New Area in Shanghai Municipality on Promoting the Construction of Zhangjiang Biomedical Industry Innovation High Ground," was officially promulgated. Article 20 explicitly proposes to "advance the integration of scientific and technological achievements with clinical research and promote the deep integration of industry, academia, research, and medicine."

As an important base for Shanghai's biopharmaceutical industry, Zhangjiang has now formed a coordinated development pattern with Zhangjiang Pharm Valley as the headquarters for R&D, and the International Medical Park, Innovative Drug Base, and Medical Device Industrial Park as manufacturing hubs, gathering over 2,300 biopharmaceutical companies.

The growth of Shanghai Baiyi Medical Technology Co., Ltd. is a microcosm of how the biopharmaceutical industry ecosystem in Zhangjiang empowers corporate innovation. As the core area of Shanghai's biopharmaceutical industry, Zhangjiang Science City not only gathers abundant clinical resources and research institutions but also gradually forms a "medical-enterprise integration" collaborative innovation mechanism.

With the platform advantages of Zhangjiang, Shanghai Baiyi Medical Technology Co., Ltd. has been able to rapidly advance technology iteration and product transformation, gradually achieving independent research and development as well as industrialization of high-end medical equipment. The company stated that it will continue to adhere to the development strategy of "clinically-driven and innovation-led" in the future, cooperating with more top-tier medical institutions to promote China-produced innovative medical equipment to the global stage.

As China's support for the high-end medical device industry continues to increase, Zhangjiang is expected to see more "innovative seeds" like Shanghai Baiyi Medical Technology Co., Ltd., injecting strong momentum into the self-reliance and global competitiveness of China's medical equipment.

Source: Zhangjiang Headline

Editor: Liu Guangyao

Editor: Meijie

Previous Review

Zhangjiang Water Ring Sets New Benchmark for Riverside Living, Phase I Project Planned to Break Ground in Q1 Next Year

2025-09-28

Zhangjiang Scientists' Apartments Officially Completed! Building the Dream of Talent Housing

2025-09-23

【Liberation Daily Front Page】Create a "Home for Global AI Dreamers"! Zhangjiang AI Innovation Town Unveiled, to Attract Over 500 New Companies by the Year After Next

2025-09-17

Recently, Mashi-Sala (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Mashi-Sala") announced the completion of an over 100-million-yuan B+ round of financing. This round of financing was jointly led by industrial investors Bailian Commerce Investment and Bailian Zhigao, with existing shareholders H&H Fund and H&H Capital continuing to increase their investments. WinX Capital continued to serve as the exclusive financial advisor.

The successful completion of this round of financing marks the company's continuous advancement in the field of medical nutrition. The funds raised will be mainly used for strengthening the ongoing R&D investment in core products, advancing clinical trials, and further consolidating the company's leading advantages in both "clinical and consumer" scenarios.

It is reported that on February 19, 2025, Mashitha announced the completion of a nearly 200 million yuan Series B financing round. This round was jointly led by funds under CICC Capital, Hongsheng Capital, and Honghui Fund, with participation from Fengqiao Capital and Frees Fund. WinX Capital served as the exclusive financial advisor.

Methuselah is an innovative enterprise focused on medical nutrition, with over a decade of industry experience. It has established a full-matrix layout encompassing three major product systems: formula foods for special medical purposes, energy-control weight management nutritional foods, and DGI foods. Currently, the company offers more than a hundred SKUs of medical nutrition products, holds six special medical food approvals and FDA registration qualifications, meeting the diverse needs of populations ranging from clinical treatment to chronic disease management and daily health intervention. Among these, the special medical products are widely used in hospital clinics, providing precise medical-grade nutritional support for patients with various diseases; the energy-control series targets overweight, obese, and health-managed populations, enabling full-scene meal replacement interventions for patients; the DGI series focuses on special groups such as diabetics and those with gestational hyperglycemia, comprehensively fulfilling patients' low glycemic diet management needs.

Relying on the specialized R&D centers for medical foods established in Shanghai and Taizhou, the company systematically structures its R&D system, continuously advancing full-chain innovation from basic formulations and functional ingredients to clinical validation. Among these efforts, the company is increasingly investing in the development of its medical food product pipeline, steadily progressing with the R&D of multiple disease-specific total nutrition projects focused on key areas such as diabetes, cancer, and surgical trauma. Both the clinical value and product approval efficiency are at industry-leading levels. With a solid foundation of clinical collaborations and profound academic expertise, Masher's R&D capabilities are becoming the core engine driving innovation in the medical food industry and the company’s differentiated growth.

In terms of commercialization, the company has established a collaborative model of "in-depth cultivation in hospitals + expansion outside hospitals." Inside hospitals, it has partnered with over 30 core hospitals across China, jointly building nutritional discipline systems focused on key diseases such as oncology, neurology, and surgery, while providing patients with professional medical-grade nutritional services to enhance recovery quality. Outside hospitals, the company leverages its clinical resource advantages to successfully enter large chain supermarkets and health retail channels such as Bailian, Sam's Club, and Costco, promoting the concept of medical nutrition to a broader consumer base. Its product, DGI® Nut Crisp, as the first low-GI nut product in China, has become the single-item sales champion in its category at Sam's Club, demonstrating the company's strong market competitiveness in the retail sector.

Regarding this round of financing, Tang Liming, founder of MashiSala, stated that in the future, MashiSala will continue to deepen product innovation, promote the wider availability of medical nutrition for patients and the general public, and contribute to the realization of the Healthy China strategy.

Editor: Jin Fei

Source: "Win Capital" Official Account